The American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) continue to recommend human insulin as the standard of care in pregnant women with diabetes mellitus and gestational diabetes mellitus (GDM) requiring medical therapy
Its local pharmacological characteristics provide a new idea for the treatment of obesity.AOD 9604, as an anti-obesity polypeptide targeting subcutaneous adipose tissue, achieves the effect of local fat reduction by activating lipolysis and inhibiting fat production
Fat loss data, dosing, side effects, cost, and stacking protocols
The FDA has not approved BPC-157 for clinical use
Some patients may require an even higher dose of 2 mg weekly for optimal effect, particularly for weight management indications, though this should be approached cautiously with careful monitoring for adverse effects